SFDA Considers Importing Semi-Finished Blood Products
This article was originally published in PharmAsia News
Executive Summary
Due to blood plasma shortages, China's major blood product companies often operate below capacity, leading to severe supply shortages on blood products. Hualan Biological Engineering, China's largest blood product producer, which accounts for 40 percent of the domestic market, has suspended output for four months in the past three quarters, further worsening the dire status. Responding to the situation, China's State FDA revealed that it is considering allowing the import of semi-finished blood products to ease local blood plasma shortages. Because blood products are linked to national security, China has no relevant policies and criteria for import and export. Thus, preparatory groundwork will be needed for semi-finished product imports. (Click here for more - Chinese Language)